Hematology & Oncology
Division Chief Hematology and Oncology
 |
Jan S. Moreb, M.D. Professor Bone Marrow Transplant Program University of Florida, Department of Medicine 1600 SW Archer Road/Box 100277 Gainesville, FL 32610-0277 (352) 273-7832/FAX (352) 371-0370 |
Dr Moreb is a physician scientist who maintains basic and clinical research expertise. He is board certified in Internal Medicine and Hematology. He is well published with a focus on multiple myeloma and stem cell transplantation. He is a member of many medical societies including the American Society of Hematology, the American Association for Cancer Research, and the American Society for Blood and Marrow Transplantation.
Training:
| Degree Program |
Institution | Field/Specialty |
| MD | Hebrew University Hadassah Medical School, Jerusalem, Israel | Medicine |
| Internship | Hadassah University Hospital, Jerusalem, Israel | Medicine |
| Residency | Hadassah University Hospital, Jerusalem, Israel | Hematology |
| Resident and Chief Resident | Shaare-Zedek University Hospital, Jerusalem, Israel | Internal Medicine |
| Fellowship | University of Florida, College of Medicine, Gainesville, Florida | Medical Oncology and Hematology |
Academic Interests:
His areas of specialization in the laboratory research are in drug resistance, gene expression, and cell biology. His research interests and activities have involved laboratory research focused on aldehyde dehydrogenases (ALDH) isozymes and their role in drug resistance of hematopoietic stem cells (HSC) as well as cancer cells and more recently as a possible marker for lung cancer stem cell.
In addition, he is active in different clinical research projects. These involve different aspects of stem cell transplantation (SCT) including stem cell mobilization, engraftment, and the use of new methods to improve outcomes after autologous SCT (ASCT) for myeloma. Tandem transplants, post-transplant maintenance therapy, including adoptive immunotherapy and Phase I-III for Multiple Myeloma are his current areas of interest.
Clinical Interests:
Dr Moreb has focused his efforts on taking care of patients with multiple myeloma in addition to other hematologic malignancies. He has gained the respect of his peers from around the country and the reputation as one of the experts on multiple myeloma and other related monoclonal gammopathies.
Publications:
- Moreb JS, Muhoczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 2007; 59:127-136. Epub 2006 Apr 14
- Moreb JS, Zucali JR, Ostmark B, Benson NA. Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom 2007; 72:281-289.
- Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: Correlation with histologic type and potential precursors. Lung Cancer 2008; 59:340-349.
- Liu H, Yuan CM, Heinerich J, Braylan RC, Chang MN, Wingard JR, Moreb JS. Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma undergoing Autologous Stem Cell Transplantation: A Retrospective Study. Leuk Lymphoma 2008; 49:306-314.
- Han S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther 2008; 16:269-279.